NeuroSense Therapeutics Ltd. (NRSN) Key Statistics & Financial Ratios

NeuroSense Therapeutics Ltd. (NRSN) — Price $6.49 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for NeuroSense Therapeutics Ltd. (NRSN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).

Stock Data

Price$6.49
Market Cap$11M
Enterprise Value$12.4M
Beta1.68
ExchangeNASDAQ
CountryIL

Valuation Multiples

P/E Ratio-0.79
Price / Book-5.76
P/S0.00
EV/EBITDA-1.12
EV/Sales0.00
EV/FCF-3.38
P/FCF-3.38
Earnings Yield-123.83%
FCF Yield-29.58%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity1070.23%
Return on Assets-1082.20%
Return on Invested Capital797.48%
Return on Capital Employed744.96%

Financial Health

Current Ratio0.31
Quick Ratio0.31
Cash Ratio0.07
Debt / Equity-0.11
Debt / Assets16.54%
Net Debt / EBITDA-0.00
Interest Coverage-652.06

Per-Share Data

Revenue per share0.00
Book Value per share-1.22
Cash per share0.13
FCF per share-2.88
Tangible Book Value per share-1.22
Dividend per share0.00

Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRXS · RLYB

Explore sector: Healthcare · Biotechnology

More sections of NRSN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks